Question 145: Was GVHD prophylaxis planned?

After allogeneic HCT, specific immunosuppressive therapy may be administered to prevent GVHD or to immunosuppress the host marrow, thereby promoting engraftment of the donor stem cells. Most transplant centers have specific GVHD prophylaxis protocols and graft rejection protocols. Planned agents a recipient receives as a result of these protocols should be included in this section. This answer does not have to match what is reported on the Post-Infusion Follow-Up (2100) Form.

Indicate if GVHD prophylaxis was planned at the time of transplant. If GVHD prophylaxis was not planned at the time of transplant, check No, and continue with question 148.

Questions 146 – 147: Specify drugs / intervention (check all that apply)

The prophylactic drug options listed on the form are intended to be administered in a systemic or oral form. If the recipient received one of the listed drugs in a topical form, select the “other agent” option and specify the drug in question 147.

The Pre-TED Form lists the generic chemotherapy drug names. The following website provides the trade names under which generic drugs are manufactured:

If GVHD prophylaxis is used for a syngeneic (monozygotic or identical twin) or autologous HCT, attach a copy of the source document using the attachment feature in FormsNet3SM.

Section Updates:

Question Number Date of Change Add/Remove/Modify Description Reasoning (If applicable)
Q145 3/27/2022 Remove Updated red box above question 145 for when GVHD prophylaxis questions are required to be answered: The following GVHD prophylaxis questions are to be completed for allogeneic HCTs only. Autologous and syngeneic HCTs continue with question 148. Due to change in form validations
Last modified: Mar 27, 2022

Need more help with this?
Don’t hesitate to contact us here.

Was this helpful?

Yes No
You indicated this topic was not helpful to you ...
Could you please leave a comment telling us why? Thank you!
Thanks for your feedback.